Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB8761 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal IGFBP-6 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human IGFBP-6 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant human (rh) IGFBP-1, -2, -3, -4, -5, rmIGFBP-3, -5, or -6.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 500 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker.
Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Chen Q, Qin S, Liu Y, Hong M, Qian CN, Keller ET, Zhang J, Lu Y
Oncotarget 2016 Oct 18;7(42):68140-68150
Oncotarget 2016 Oct 18;7(42):68140-68150
Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
Hu H, Kwun J, Aizenstein BD, Knechtle SJ
Transplantation 2009 Jun 27;87(12):1814-20
Transplantation 2009 Jun 27;87(12):1814-20
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
Biochemical and biophysical research communications 2005 Aug 5;333(3):1011-6
Biochemical and biophysical research communications 2005 Aug 5;333(3):1011-6
No comments: Submit comment
No validations: Submit validation data